Reference
1. Kato ET, Goto S, Giugliano RP: Overview of oral antithrombotic treatment in elderly patients with atrial fibrillation .Ageing research reviews 2019, 49 :115-124.
2. Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M, Cattarinussi A, D’Alfonso MG, Gradia C, Sgherzi B et al :Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project . Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2019, 21 (10):1468-1475.
3. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE: What is polypharmacy? A systematic review of definitions . BMC geriatrics2017, 17 (1):230.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J et al :Dabigatran versus warfarin in patients with atrial fibrillation . The New England journal of medicine 2009,361 (12):1139-1151.
5. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J et al :Edoxaban versus warfarin in patients with atrial fibrillation .The New England journal of medicine 2013,369 (22):2093-2104.
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A et al : Apixaban versus warfarin in patients with atrial fibrillation . The New England journal of medicine 2011, 365 (11):981-992.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP et al : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation . The New England journal of medicine 2011, 365 (10):883-891.
8. Eggebrecht L, Nagler M, Göbel S, Lamparter H, Keller K, Wagner B, Panova-Noeva M, Ten Cate V, Bickel C, Lauterbach M et al :Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists . Journal of the American Geriatrics Society 2019, 67 (3):463-470.
9. Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L et al :Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial .BMJ (Clinical research ed) 2016, 353 :i2868.
10. Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW et al :Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation . Circulation 2016, 133 (4):352-360.
11. Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K et al : 2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary .Thrombosis and haemostasis 2022, 122 (1):20-47.
12. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PEet al : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC . European heart journal 2021, 42 (5):373-498.
13. Fincke BG, Miller DR, Spiro A, 3rd: The interaction of patient perception of overmedication with drug compliance and side effects . Journal of general internal medicine 1998,13 (3):182-185.
14. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults .Journal of the American Geriatrics Society 2019,67 (4):674-694.
15. Lip GYH, Keshishian A, Kang A, Dhamane AD, Luo X, Klem C, Rosenblatt L, Mardekian J, Jiang J, Yuce H et al : Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy . European heart journal Cardiovascular pharmacotherapy 2021, 7 (5):405-414.
16. Harskamp RE, Teichert M, Lucassen WAM, van Weert H, Lopes RD:Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation . Cardiovascular drugs and therapy 2019,33 (5):615-623.
17. Feng X, Sambamoorthi U, Innes K, Castelli G, LeMasters T, Xiong L, Williams MU, Tan X: Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants . Cardiovascular drugs and therapy 2018, 32 (6):591-600.
18. Brais C, Larochelle J, Turgeon MH, Blais L, Farand P, Perreault S, Letemplier G, Beauchesne MF: Predictors of Direct Oral Anticoagulants Utilization for Thromboembolism Prevention in Atrial Fibrillation . Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 2017, 20 :8-14.
19. Momo K, Shu-Toh K, Kaneko M, Yamanaka N, Oto Y, Tanaka K, Koinuma M, Sasaki T: Predictive factors associated with bleeding in atrial fibrillation patients treated with anti-coagulant drugs using a large claims database . PloS one 2020, 15 (8):e0238233.
20. Admassie E, Chalmers L, Bereznicki LR: Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study .European journal of clinical pharmacology 2017,73 (12):1681-1689.
21. Jang BM, Lee OS, Shin EJ, Cho EJ, Suh SY, Cho YS, Koo Lee M, Rhie SJ: Factors related to inappropriate edoxaban use .Journal of clinical pharmacy and therapeutics 2019,44 (5):760-767.
22. Marco Garbayo JL, Koninckx Cañada M, Pérez Castelló I, Faus Soler MT, Perea Ribis M: Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban .European journal of hospital pharmacy : science and practice2019, 26 (2):106-112.
23. Alberts MJ, He J, Kharat A, Ashton V: Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy . Am J Cardiovasc Drugs 2022, 22 (4):425-436.
24. Berger JS, Laliberte F, Kharat A, Lejeune D, Moore KT, Jung Y, Lefebvre P, Ashton V: Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US) .Adv Ther 2021, 38 (7):3771-3788.
25. Chen N, Alam AB, Lutsey PL, MacLehose RF, Claxton JS, Chen LY, Chamberlain AM, Alonso A: Polypharmacy, Adverse Outcomes, and Treatment Effectiveness in Patients >/=75 With Atrial Fibrillation . J Am Heart Assoc 2020, 9 (11):e015089.
26. Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke AK, Eriksson D, Coleman CI: Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation . Pharmacotherapy 2019,39 (2):196-203.
27. Mentias A, Heller E, Vaughan Sarrazin M: Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy . Stroke 2020,51 (7):2076-2086.
28. Millenaar D, Schumacher H, Brueckmann M, Eikelboom JW, Ezekowitz M, Slawik J, Ewen S, Ukena C, Wallentin L, Connolly S et al :Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial) . Am J Cardiol 2021,149 :27-35.
29. van den Dries CJ, van Doorn S, Souverein P, Pajouheshnia R, Moons KGM, Hoes AW, Geersing GJ, van den Ham HA: The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation . TH Open 2020,4 (4):e417-e426.
30. Yamashita T, Akao M, Atarashi H, Ikeda T, Koretsune Y, Okumura K, Shimizu W, Suzuki S, Tsutsui H, Toyoda K et al : Effect of Polypharmacy on Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation - A Sub-Analysis of the ANAFIE Registry .Circ J 2022.
31. Polzin A, Dannenberg L, Wolff G, Helten C, Achilles A, Hohlfeld T, Zeus T, Kelm M, Massberg S, Petzold T: Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition? Pharmacology & therapeutics 2019, 195 :1-4.
32. Hellwig T, Gulseth M: Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? The Annals of pharmacotherapy2013, 47 (11):1478-1487.
33. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V et al :The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation . European heart journal 2018,39 (16):1330-1393.
34. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance .Clinical therapeutics 2001, 23 (8):1296-1310.
35. Barnes GD, Nallamothu BK, Sales AE, Froehlich JB:Reimagining Anticoagulation Clinics in the Era of Direct Oral Anticoagulants . Circulation Cardiovascular quality and outcomes2016, 9 (2):182-185.
36. Komen JJ, Pottegård A, Mantel-Teeuwisse AK, Forslund T, Hjemdahl P, Wettermark B, Hellfritzsch M, Hallas J, Olesen M, Bennie M et al :Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries . Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2021,23 (11):1722-1730.